Trials / Completed
CompletedNCT03394144
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9150, Durvalumab | After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT |
Timeline
- Start date
- 2018-01-30
- Primary completion
- 2019-04-12
- Completion
- 2019-04-12
- First posted
- 2018-01-09
- Last updated
- 2019-06-24
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03394144. Inclusion in this directory is not an endorsement.